Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brenda Crowe

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
The Journal of Clinical Endocrinology and Metabolism|April 5, 2002
Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS DatabaseAndrea F Attanasio, Peter C Bates, Ken K Y Ho, et al.
Lancet (London, England)|February 27, 2023
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)Eric F Morand, Edward M Vital, Michelle Petri, et al.
Lupus Science & Medicine|October 10, 2020
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathwaysThomas Dörner, Yoshiya Tanaka, Michelle A Petri, et al.
The Lancet. Respiratory Medicine|September 4, 2021
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialVincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The Journal of Clinical Endocrinology and Metabolism|April 5, 2002
Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS DatabaseAndrea F Attanasio, Peter C Bates, Ken K Y Ho, et al.
Lancet (London, England)|February 27, 2023
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)Eric F Morand, Edward M Vital, Michelle Petri, et al.
Lupus Science & Medicine|October 10, 2020
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathwaysThomas Dörner, Yoshiya Tanaka, Michelle A Petri, et al.
The Lancet. Respiratory Medicine|September 4, 2021
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialVincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, et al.
Pageof 2